Alexander Spiess, MD
Surgery of the Hand · Trafford, PANPI 1245255447
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,950 of the $7,485 with a category attached, or 92.8%. Axogen accounts for 65.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $4,849 and has fallen 99.0% since, to $48 in 2024.
Across 12 payments — averaging $623.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axogen$5K
- Checkpoint Surgical, Inc$2K
- Endo Pharmaceuticals Inc.$71
- Bioventus LLC$70
- Integra Lifesciences Corporation$17
- Endo USA, Inc.$16
- plus $14 from 1 others
Across 8 payments — averaging $5759.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Axogen$46K
What the payments were for
- Consulting fees$6,95093%
- Food & beverage$5357%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axogen | 3 | $4,897 |
| Checkpoint Surgical, Inc | 1 | $2,400 |
| Endo Pharmaceuticals Inc. | 4 | $71 |
| Bioventus LLC | 1 | $70 |
| Integra Lifesciences Corporation | 1 | $17 |
| Endo USA, Inc. | 1 | $16 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,485 in reported general payments places this provider in the 70th percentile of 20 surgery of the hand providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 13 | $365 |
| Cephalexin | 36 | $63 |
| Naproxen | 36 | $56 |
| Oxycodone Hcl | 32 | $50 |
| Azithromycin | 29 | $46 |
Paid to pharmacies, not to this prescriber.
Other surgery of the hand in Trafford
- Joel KlenaDanville$56K
- Robert KangPittsburgh$27K
- Jason YooPittsburgh$19K
- Nathan MillerAllentown$11K
- Scott EisenhuthState College$10K
- Eugene ParkPhiladelphia$6K
- Dana LavantureSayre$5K
- Debra BournePittsburgh$4K
- Christopher LincoskiState College$3K
- George ZavitsanosFort Washington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.